Disorders of biopterin metabolism
Defects in the metabolism or regeneration of tetrahydrobiopterin (BH4) were initially discovered in patients with hyperphenylalaninaemia who had progressive neurological deterioration despite optimal metabolic control (malignant hyperphenylalaninaemia). BH4 is an essential cofactor not only for phenylalanine hydroxylase, but also for tyrosine and two tryptophan hydroxylases, three nitric oxide synthases, and glyceryl-ether monooxygenase. Defective activity of tyrosine and tryptophan hydroxylases explains the neurological deterioration in patients with BH4 deficiency with progressive mental and physical retardation, central hypotonia and peripheral spasticity, seizures and microcephaly. Five separate genetic conditions affect BH4 synthesis or regeneration: deficiency of GTP cyclohydrolase I, 6-pyruvoyl tetrahydropterin synthase, sepiapterin reductase, dihydropteridine reductase (DHPR) and pterin-4α-carbinolamine dehydratase. Only the latter of these conditions is relatively benign and is associated with transient hyperphenylalaninaemia. All these conditions can be identified in newborns by an elevated phenylalanine, with the exception of sepiapterin reductase and the dominant form of GTP cyclohydrolase I deficiency that results in biopterin deficiency/insufficiency only in the brain. Diagnosis relies on the measurement of pterin metabolites in urine, dihydropteridine reductase in blood spots, neurotransmitters and pterins in the CSF and on the demonstration of reduced enzyme activity (red blood cells or fibroblasts) or causative mutations in the relative genes. The outcome of BH4 deficiency is no longer malignant if therapy is promptly initiated to reduce plasma phenylalanine levels and replace missing neurotransmitters. This is accomplished by a special diet and/or BH4 supplements and administration of l-dopa, carbidopa, 5-hydroxytryptophan, and, in certain cases, a MAO-B inhibitor. Patients with DHPR deficiency also require folinic acid supplements, since DHPR may help in maintaining folate in the tetrahydro form. Several patients with BH4 deficiency treated since the newborn period have reached adult age with good outcome.
KeywordsAldose Reductase Pterin Biopterin Phenylalanine Level Dihydropteridine Reductase
GTP cyclohydrolase I feedback regulatory protein
GTP cyclohydrolase I
I thank Drs Lorenzo Botto and Marzia Pasquali for reviewing this manuscript.
- Concolino D, Muzzi G, Rapsomaniki M, Moricca MT, Pascale MG, Strisciuglio P (2008) Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. J Inherit Metab Dis. doi: 10.1007/s10545-007-0788-3.
- Hopkins FG (1889) Note on a yellow pigment from butterflies. Nature 40: 355.Google Scholar
- Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovic R, et al (2008) Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab 94(1): 127–131. doi: 10.1016/j.ymgme.2008.01.003.PubMedCrossRefGoogle Scholar
- Katusic ZS, d’Uscio LV, Nath KA (2009) Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 30(1): 48–54.Google Scholar
- Kaufman S, Kapatos G, McInnes RR, Schulman JD, Rizzo WB (1982) Use of tetrahydropterins in the treatment of hyperphenylalaninemia due to defective synthesis of tetrahydrobiopterin: evidence that peripherally administered tetrahydropterins enter the brain. Pediatrics 70(3): 376–380.PubMedGoogle Scholar
- Niederwieser A, Blau N, Wang M, Joller P, Atares M, Cardesa-Garcia J (1984) GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur J Pediatr 141(4): 208–214. doi: 10.1007/BF00572762.PubMedCrossRefGoogle Scholar
- Ogawa A, Kanazawa M, Takayanagi M, Kitani Y, Shintaku H, Kohno Y (2008) A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of l-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Brain Dev 30(1): 82–85. doi: 10.1016/j.braindev.2007.05.011.PubMedCrossRefGoogle Scholar
- Schmidt TS, Alp NJ (2007) Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 113(2): 47–63.Google Scholar
- Schopf C (1964) Die Anfange der Pterinchemie. In: Pfleiderer W, Taylor, E.D., eds. Pteridine Chemistry. Oxford: Pergamon Press, 3–14.Google Scholar
- Watschinger K, Keller MA, Hermetter A, Golderer G, Werner-Felmayer G, Werner ER (2009) Glyceryl ether monooxygenase resembles aromatic amino acid hydroxylases in metal ion and tetrahydrobiopterin dependence. Biol Chem 390(1): 3–10.Google Scholar